Amlodipine with losartan
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Comparative Efficacy and Safety of Amlodipine and Losartan in Hypertension Management
Introduction to Amlodipine and Losartan Combination Therapy
Amlodipine, a calcium channel blocker, and losartan, an angiotensin II receptor antagonist, are commonly used antihypertensive agents. Their combination is often prescribed to enhance blood pressure (BP) control, especially in patients who do not achieve target BP levels with monotherapy. This article synthesizes research findings on the efficacy, safety, and additional benefits of using amlodipine and losartan, either as monotherapies or in combination.
Blood Pressure Control and Efficacy
Superior BP Reduction with Combination Therapy
Studies have shown that the combination of amlodipine and losartan is more effective in reducing BP compared to losartan alone. In a multicenter, double-blind, randomized trial, patients treated with a single-pill combination of amlodipine/losartan (AML/LOS) exhibited significantly greater reductions in both systolic and diastolic BP compared to those treated with losartan alone. This enhanced efficacy was evident at both 4 and 8 weeks of treatment, with higher BP target achievement rates in the AML/LOS group.
Comparison with Other Combinations
When compared to other combination therapies, such as losartan/hydrochlorothiazide (L/H), the amlodipine/losartan combination demonstrated superior efficacy in reducing 24-hour brachial and central BP, particularly in patients with advanced arterial stiffness. This suggests that the AML/LOS combination may be particularly beneficial for patients with more severe hypertension or arterial stiffness.
Renal Protection and Proteinuria Reduction
Losartan's Renoprotective Effects
Losartan has been shown to significantly reduce proteinuria in patients with chronic kidney disease (CKD) and hypertension, an effect not observed with amlodipine. In the JLIGHT study, losartan reduced 24-hour urinary protein excretion by up to 47.9% over 12 months, whereas amlodipine did not affect proteinuria levels. This renoprotective effect of losartan is attributed to mechanisms beyond BP control, potentially involving the reduction of glomerular pressure and filtration fraction.
Effects in Non-Diabetic Nephropathy and Transplant Patients
In hypertensive patients with non-diabetic nephropathy, losartan decreased urinary albumin excretion significantly, while amlodipine did not. Similarly, in renal transplant recipients, losartan reduced plasma levels of transforming growth factor-beta1 (TGF-beta1), a key cytokine in fibrosis, whereas amlodipine had no effect on TGF-beta1 levels. These findings highlight losartan's additional benefits in renal protection and its potential role in managing chronic allograft nephropathy.
Safety and Tolerability
Adverse Events and Quality of Life
Both amlodipine and losartan are generally well-tolerated, but their side effect profiles differ. A study comparing losartan and amlodipine found that amlodipine was associated with a higher incidence of peripheral edema, while losartan was more likely to cause dizziness upon standing. Additionally, losartan was associated with fewer drug-related adverse events and withdrawals from therapy compared to amlodipine.
Pharmacokinetics and Tolerability in Healthy Subjects
A pharmacokinetic study comparing fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan found similar pharmacokinetic profiles and tolerability between the two formulations. This suggests that both combinations are viable options for patients requiring dual therapy.
Conclusion
The combination of amlodipine and losartan offers superior BP control compared to losartan monotherapy and other combinations like losartan/hydrochlorothiazide. Losartan provides significant renoprotective benefits, particularly in reducing proteinuria and TGF-beta1 levels, which are not observed with amlodipine. Both drugs are well-tolerated, but their side effect profiles should be considered when choosing the appropriate therapy for individual patients. Overall, the amlodipine/losartan combination is an effective and safe option for managing hypertension, especially in patients with additional renal concerns.
Sources and full results
Most relevant research papers on this topic